Pay in 4 interest-free payments of $6.32 Learn more
Ships within 48 hours · Estimated delivery Nov 5 - Nov 10
However, prescribing rates remained relatively steady and even decreased slightly through late 2024 and early 2025
TE has previously been reported in patients following weight loss (bariatric) surgery
doi:10.1016/j.clnu.2020.07.019 Wilding JPH, Batterham RL, Calanna S, et al
The side effects most people experience include nausea, vomiting, diarrhea, constipation, stomach upset, or other GI-related issues
Key findings from this phase 2 obesity trial included: Mean weight reduction of up to approximately 24.2% at the highest dose (12 mg) after 48 weeks Dose-dependent reductions in body weight across all active treatment arms Significant reductions in waist circumference, blood pressure, and lipid parameters Improvements in fasting glucose and insulin resistance markers A separate phase 2 trial in adults with type 2 diabetes (published in 2023) demonstrated meaningful HbA1c reductions alongside substantial weight loss, suggesting potential dual utility in both obesity and glycaemic management
